Cargando…
AI-powered drug repurposing for developing COVID-19 treatments
Emerging infectious diseases are an ever-present threat to public health, and COVID-19 is the most recent example. There is an urgent need to develop a robust framework to combat the disease with safe and effective therapeutic options. Compared to de novo drug discovery, drug repurposing may offer a...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865759/ http://dx.doi.org/10.1016/B978-0-12-824010-6.00005-8 |
_version_ | 1784655696447406080 |
---|---|
author | Liu, Zhichao Chen, Xi Carter, Wendy Moruf, Alicia Komatsu, Takashi E. Pahwa, Sonia Chan-Tack, Kirk Snyder, Kevin Petrick, Nicholas Cha, Kenny Lal-Nag, Madhu Hatim, Qais Thakkar, Shraddha Lin, Yu Huang, Ruili Wang, Dong Patterson, Tucker A. Tong, Weida |
author_facet | Liu, Zhichao Chen, Xi Carter, Wendy Moruf, Alicia Komatsu, Takashi E. Pahwa, Sonia Chan-Tack, Kirk Snyder, Kevin Petrick, Nicholas Cha, Kenny Lal-Nag, Madhu Hatim, Qais Thakkar, Shraddha Lin, Yu Huang, Ruili Wang, Dong Patterson, Tucker A. Tong, Weida |
author_sort | Liu, Zhichao |
collection | PubMed |
description | Emerging infectious diseases are an ever-present threat to public health, and COVID-19 is the most recent example. There is an urgent need to develop a robust framework to combat the disease with safe and effective therapeutic options. Compared to de novo drug discovery, drug repurposing may offer a lower-cost and faster drug discovery paradigm to explore potential treatment options of existing drugs. This chapter elucidates the advantages of artificial intelligence (AI) in enhancing the drug repurposing process from a data science perspective, using COVID-19 as an example. First, we elaborate on how AI-powered drug repurposing benefits from the accumulated data and knowledge of COVID-19 natural history and pathogenesis. Second, we summarize the pros and cons of AI-powered drug repurposing strategies to facilitate fit-for-purpose selection. Finally, we outline challenges of AI-powered drug repurposing from a regulatory perspective and suggest some potential solutions. |
format | Online Article Text |
id | pubmed-8865759 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-88657592022-02-24 AI-powered drug repurposing for developing COVID-19 treatments Liu, Zhichao Chen, Xi Carter, Wendy Moruf, Alicia Komatsu, Takashi E. Pahwa, Sonia Chan-Tack, Kirk Snyder, Kevin Petrick, Nicholas Cha, Kenny Lal-Nag, Madhu Hatim, Qais Thakkar, Shraddha Lin, Yu Huang, Ruili Wang, Dong Patterson, Tucker A. Tong, Weida Reference Module in Biomedical Sciences Article Emerging infectious diseases are an ever-present threat to public health, and COVID-19 is the most recent example. There is an urgent need to develop a robust framework to combat the disease with safe and effective therapeutic options. Compared to de novo drug discovery, drug repurposing may offer a lower-cost and faster drug discovery paradigm to explore potential treatment options of existing drugs. This chapter elucidates the advantages of artificial intelligence (AI) in enhancing the drug repurposing process from a data science perspective, using COVID-19 as an example. First, we elaborate on how AI-powered drug repurposing benefits from the accumulated data and knowledge of COVID-19 natural history and pathogenesis. Second, we summarize the pros and cons of AI-powered drug repurposing strategies to facilitate fit-for-purpose selection. Finally, we outline challenges of AI-powered drug repurposing from a regulatory perspective and suggest some potential solutions. 2022 2022-02-23 /pmc/articles/PMC8865759/ http://dx.doi.org/10.1016/B978-0-12-824010-6.00005-8 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Liu, Zhichao Chen, Xi Carter, Wendy Moruf, Alicia Komatsu, Takashi E. Pahwa, Sonia Chan-Tack, Kirk Snyder, Kevin Petrick, Nicholas Cha, Kenny Lal-Nag, Madhu Hatim, Qais Thakkar, Shraddha Lin, Yu Huang, Ruili Wang, Dong Patterson, Tucker A. Tong, Weida AI-powered drug repurposing for developing COVID-19 treatments |
title | AI-powered drug repurposing for developing COVID-19 treatments |
title_full | AI-powered drug repurposing for developing COVID-19 treatments |
title_fullStr | AI-powered drug repurposing for developing COVID-19 treatments |
title_full_unstemmed | AI-powered drug repurposing for developing COVID-19 treatments |
title_short | AI-powered drug repurposing for developing COVID-19 treatments |
title_sort | ai-powered drug repurposing for developing covid-19 treatments |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865759/ http://dx.doi.org/10.1016/B978-0-12-824010-6.00005-8 |
work_keys_str_mv | AT liuzhichao aipowereddrugrepurposingfordevelopingcovid19treatments AT chenxi aipowereddrugrepurposingfordevelopingcovid19treatments AT carterwendy aipowereddrugrepurposingfordevelopingcovid19treatments AT morufalicia aipowereddrugrepurposingfordevelopingcovid19treatments AT komatsutakashie aipowereddrugrepurposingfordevelopingcovid19treatments AT pahwasonia aipowereddrugrepurposingfordevelopingcovid19treatments AT chantackkirk aipowereddrugrepurposingfordevelopingcovid19treatments AT snyderkevin aipowereddrugrepurposingfordevelopingcovid19treatments AT petricknicholas aipowereddrugrepurposingfordevelopingcovid19treatments AT chakenny aipowereddrugrepurposingfordevelopingcovid19treatments AT lalnagmadhu aipowereddrugrepurposingfordevelopingcovid19treatments AT hatimqais aipowereddrugrepurposingfordevelopingcovid19treatments AT thakkarshraddha aipowereddrugrepurposingfordevelopingcovid19treatments AT linyu aipowereddrugrepurposingfordevelopingcovid19treatments AT huangruili aipowereddrugrepurposingfordevelopingcovid19treatments AT wangdong aipowereddrugrepurposingfordevelopingcovid19treatments AT pattersontuckera aipowereddrugrepurposingfordevelopingcovid19treatments AT tongweida aipowereddrugrepurposingfordevelopingcovid19treatments |